Whole-gland low-dose rate (LDR) brachytherapy has been a well-established modality of treating low-risk prostate cancer.
Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs. Focal treatment using LDR brachytherapy has been relatively unexplored, but it may offer advantages over other modalities that have established experiences with a focal approach. This is particularly true as prostate cancer is being detected at an earlier and more localized stage with the advent of better detection methods and newer imaging modalities.
Written by:
Tong WY, Cohen G, Yamada Y. Are you the author?
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Reference: Cancer Manag Res. 2013 Sep 13;5:315-25.
doi: 10.2147/CMAR.S33056
PubMed Abstract
PMID: 24049459
UroToday.com Prostate Cancer Section
